Imagine if we could treat severe pain like a personalized prescription, but instead of pills, we used a smart device at home. This project finds biological 'fingerprints' in the brain to predict who will respond to specific treatments. It then uses a gentle electrical stimulation device to dial down pain without the side effects of heavy medication.
20% of cancer patients do not respond to standard pain medications, and existing non-drug alternatives are often too invasive or expensive. This creates a gap in palliative care where patients suffer despite available pharmacological options.
A home-based, remotely-supervised non-invasive transcranial electric stimulation (tES) system and a customized web portal for patient management and biomarker tracking.
If you are a hardware manufacturer dealing with the high cost and risk of invasive surgical implants — this project developed a home-based, non-invasive transcranial electric stimulation (tES) system that reduces the need for opioids by at least 50%.
If you are a software provider dealing with poor patient adherence in palliative care — this project developed a customized web portal for remotely-supervised treatment and medication diaries to improve clinical management.
If you are a clinic operator dealing with the 20% of cancer patients who do not respond to standard drugs — this project developed a biomarker-based stratification method to avoid trial-and-error prescribing.
Based on available project data, the specific price per unit is not listed, but the project aims to create a cost-effective alternative to expensive and invasive neurosurgical procedures.
The project includes a pilot study with 450 patients and a techno-economic analysis to assess the possibilities of implementation across different European healthcare systems.
Based on available project data, specific patents are not listed, but the project involves 5 industry partners and 4 SMEs, suggesting a structured approach to results exploitation.
It integrates via a customized web portal and a medication diary, allowing for remotely-supervised home treatment and better data sharing between patients and caregivers.
The project runs from 2022-06-01 to 2027-05-31, indicating that full validation and Health Technology Assessment will be completed by mid-2027.
The consortium is highly balanced for commercialization, featuring 19 partners across 10 countries. With a 26% industry ratio (5 industry partners, 4 of which are SMEs), there is a strong bridge between the 4 universities and 4 research centers and the actual market. This structure suggests that the technical development is being closely monitored for commercial viability and regulatory compliance.
Contact the Universidad de Santiago de Compostela regarding the tES home-based system
Contact us to identify licensing opportunities for the neuromodulation biomarkers.
